Author, publication year | Cohort, country | Design, follow-up years | Population, cases/total no. of subjects | Age (years), female (%), and ethnicity | BMI (kg/m2), thyroid medicine users (%) | Outcomes | Covariates adjusted in models |
---|---|---|---|---|---|---|---|
M Thvilum, 2013Â [32] | Official Danish health registers study, Denmark | Prospective cohort study, mean: 6 years | Danish national patient registry population, 1020/14,480 | Mean: 58, 84% of women, NR | NR, no | T2DM | Age and sex. |
N Gronich, 2015 [2] | NR, Israel | Prospective cohort study, 5–7 years | Statin non-users 3666/20,334 | 40–80, 62.11% of women, NR | Obesity (43.63%), mixed | DM | Age, sex, race, obesity, smoking, glucose, LDL, HDL, TG, history of hypertension, and drug use. |
N Gronich, 2015 [2] | NR, Israel | Prospective cohort study, 5–7 years | Statin users, 4410/39,263 | 40–80, 62.24% of women, NR | Obesity (44.3%), mixed | DM | Age, sex, race, obesity, smoking, glucose, LDL, HDL, TG, history of hypertension, and drug use. |
J-E Jun, 2016 [33] | NR, Korea | Prospective cohort study, 7 years | Population-based, 229/6235 | ≥ 18, 41.96% of women, NR | Mean (SD): 23.7 (2.56), no | T2DM | Age, sex, BMI, HbA1c, HDL, TG, LDL, smoking, lipid drug use, hypertension, BMI change. |
L Mehran, 2016 [34] | Tehran Thyroid Study, Iran | Prospective cohort study, median: 9.73 years | Population-based, NR/2316 | ≥ 20, NR, NR | Mean (SD): 25.3 (4.3), no | High-fasting blood glucose | Age, sex, smoking, BMI, and HOMA-IR. |
L Chaker, 2016 [35] | The Rotterdam Study, Netherlands | Prospective cohort study, mean: 7.9 years | Healthy population-based, 757/8107 | Mean: 64.6, 58% of women, NR | Mean (SD):Â 26.5 (4.05), mixed | DM | Sex, age, smoking, cohort, FSG levels, insulin, SBP, DBP, antihypertensive drugs, HDL cholesterol, and BMI. |
C-H Chang, 2017 [27] | NR, China | Prospective cohort study, median: 2.6 years | Population-based, 1551/68,846 | Mean: 41.2, 52.5% of women, NR | Obesity (3.2%), no | Dysglycemia, prediabetes, and T2DM | Sex, age, education level, smoking, drinking, and obesity. |
N M.Y. Journy, 2017 [36] | U.S. radiologic technologist cohort, USA | Prospective cohort study, median: 28 years | Women, 163/75,076 | 20-89, 100% of women, multiple | NR, mixed | T2DM deaths | Baseline year, age, race, BMI, family history of breast cancer, lifestyle, reproductive factors. |
T. Ittermann, 2017a [37] | Study of Health in Pomerania, Germany | Prospective cohort study, median: 5 years | Population-based, 116/2689 | 20–79, 51.2% of women, NR | Mean (SD): 27.2 (4.7), mixed | T2DM | Age and sex. |
T. Ittermann, 2017a [37] | INTER99, Denmark | Secondary analysis of RCT, 5 years | Population-based, 142/3815 | 30–60, 49.9% of women, NR | Mean (SD): 26.3 (4.6), NR | T2DM | Age and sex. |
T. I. de Vries, 2018 [38] | SMART study, Netherlands | Prospective cohort study, 2.9–8.3 years | With high cardiovascular risk, 289/5542 | Mean: 56, 35.24% of women, NR | Mean (SD): 26.72 (4), no | T2DM | Age, sex, current smoking, total and HDL cholesterol, and triglycerides |
R-H Chen, 2019 [39] | NR, China | Prospective cohort study, 10 years | Population-based, 5485/91,120 | ≥ 18, 77.4% of women, NR | Obesity (0.7%), NR | T2DM | Age, sex, and comorbidities. |
H-S Chen, 2007 [40] | NR, China | Prospective cohort study, 3–4.3 years | T2DM patients, CVD: 61, CVD deaths: 12, deaths: 31/556 | ≥ 30, 35.07% of women, NR | Mean (SD): 26.11 (9.8), mixed | CVD events, CVD deaths, and all-cause deaths | Age, sex, HbA1c, TC, HDL, BP, BMI, smoking, medication, urinary albumin, creatinine |
C Drechsler, 2014Â [41] | NR, China | Prospective cohort study, 4 years | Diabetic hemodialysis patients, sudden death: 120 MI: 156, stroke: 70, CV events: 345, deaths: 441/ 934 | 18-80, 46.26% of women, NR | Mean (SD): 27.6 (4.98), NR | Sudden death, MI, stroke, combined CV events, all-cause death | Age, sex, atorvastatin, SBP, BMI, left ventricular hypertrophy, albumin, creatinine, N-terminal pro2B-type natriuretic peptide, ultrafiltration volume. |
J Geng, 2014 [42] | NR, China | Prospective cohort study, 2–3 years | T2DM patients, CHD: 32, new AF: 14, deaths: 10/694 | Mean: 56.1, 32.75% of women, NR | Mean (SD): 25.13 (3.63), NR | CHD events, new-AF, and all-cause deaths | Age, sex, hypertension, total cholesterol, LDL-cholesterol, smoking, SBP, DBP, and BMI. |
T I. de Vries, 2019 [26] | SMART study, Netherlands | Prospective cohort study, 3.3–9.6 years | T2DM patients, CVD: 191, deaths: 204/1265 | Mean 61, 26.64% of women, NR | Mean (SD): 29.22 (5), NR | CVD, all-cause deaths | Age, sex, smoking, history of vascular disease, eGFR, SBP, TC, and HDL-C. |